广州中医药大学学报
廣州中醫藥大學學報
엄주중의약대학학보
JOURNAL OF GUANGZHOU UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
2001年
1期
19-24
,共6页
宋建平%徐颖%欧凤珍%彭南正%李国桥%金唐山
宋建平%徐穎%歐鳳珍%彭南正%李國橋%金唐山
송건평%서영%구봉진%팽남정%리국교%금당산
疟疾,恶性/药物疗法%复方萘酚喹/治疗应用%复方萘酚 喹/投药和剂量%萘酚类/治疗应用%青蒿素/治疗应用%青蒿素/类似物和衍生物%疟原虫,恶性/药物 作用
瘧疾,噁性/藥物療法%複方萘酚喹/治療應用%複方萘酚 喹/投藥和劑量%萘酚類/治療應用%青蒿素/治療應用%青蒿素/類似物和衍生物%瘧原蟲,噁性/藥物 作用
학질,악성/약물요법%복방내분규/치료응용%복방내분 규/투약화제량%내분류/치료응용%청호소/치료응용%청호소/유사물화연생물%학원충,악성/약물 작용
【目的】进一步探索新近研制成功的复方抗疟药复方萘酚喹(由磷酸萘酚喹、双氢青蒿素和甲氧苄啶组成)治疗恶性疟的用药剂量。【方法】采用1d疗程2次分服,设总剂量4片组和2片组,评价和比较其疗效。两组分别治疗无并发症恶性疟患者各50例。【结果】2片组的退热时间与4片组相似,但原虫转阴时间明显慢于4片组,28d治愈率2片组(85.1%)亦显著低于4组片(97.8%)。且2片组出现早期(14d)原虫复燃,说明其药量不足。【结论】推荐复方萘酚喹治疗恶性疟的临床试验治疗总剂量采用3~4片为宜。
【目的】進一步探索新近研製成功的複方抗瘧藥複方萘酚喹(由燐痠萘酚喹、雙氫青蒿素和甲氧芐啶組成)治療噁性瘧的用藥劑量。【方法】採用1d療程2次分服,設總劑量4片組和2片組,評價和比較其療效。兩組分彆治療無併髮癥噁性瘧患者各50例。【結果】2片組的退熱時間與4片組相似,但原蟲轉陰時間明顯慢于4片組,28d治愈率2片組(85.1%)亦顯著低于4組片(97.8%)。且2片組齣現早期(14d)原蟲複燃,說明其藥量不足。【結論】推薦複方萘酚喹治療噁性瘧的臨床試驗治療總劑量採用3~4片為宜。
【목적】진일보탐색신근연제성공적복방항학약복방내분규(유린산내분규、쌍경청호소화갑양변정조성)치료악성학적용약제량。【방법】채용1d료정2차분복,설총제량4편조화2편조,평개화비교기료효。량조분별치료무병발증악성학환자각50례。【결과】2편조적퇴열시간여4편조상사,단원충전음시간명현만우4편조,28d치유솔2편조(85.1%)역현저저우4조편(97.8%)。차2편조출현조기(14d)원충복연,설명기약량불족。【결론】추천복방내분규치료악성학적림상시험치료총제량채용3~4편위의。
【Objective】To further study the efects of compound naphthoquine,anewly-developed anti-malaria drug which is composed of naphthoqu i ne phosphate,dihydroartemisinin and trimethoprim on falciparum malaria.【Method s】One-day course with a total dosage of 4 tables and 2 tables of compound naphthoquine was applied to treat falciparum malaria patients without complications.One h undred cases were subject to 4-tablet group(50,group A)and 2-tablet group(50, group B).【Results 】The mean fever-subsidence(MFS) time in group B was similar to group A,but the mean parasite clearance(MPC) time was longer than that in group A.Th e cure rate for 28 days of treatment was 85.1% in group B and 97.8% in group A.Parasite recrudescence(PR) within 14 days was found in group B,which indicated the dosage was inadequate.【Con c lusion】A total dosage of 3~4 tablets of compound naphthoquine for falciparum m alaria is recommended in the clinical trial.